Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P47.03 - Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2

      00:00 - 00:00  |  Presenter: Jonathan Goldman

      • Abstract

      Loading...

  • +

    P60 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - Other Biomarkers

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      P60.12 - Prevalence of c-Met overexpression (c-Met+) and Impact of Prior Lines of Treatment on c-Met Protein Expression in NSCLC

      00:00 - 00:00  |  Presenter: Monica Motwani

      • Abstract

      Loading...

  • +

    IS10 - Satellite CME Symposium by Research To Practice: Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Non-Small Cell Lung Cancer and Validated Targets Beyond EGFR

    • 05:45 - 06:45
    • 9/10/2021
    • Location: Program Auditorium
    • CME Accredited by Other Provider
    • Type: Satellite CME Symposia
    • Track: N.A.
    • +

      IS10.01 - MODULE 1: Selection and Sequencing of Therapy for Patients with Non-Small Cell Lung Cancer (NSCLC) and an ALK Rearrangement

      05:45 - 06:00

      • Abstract

      No abstract available for this presentation

    • +

      IS10.02 - MODULE 2: Current and Future Directions in the Management of ROS1-Positive NSCLC

      06:00 - 06:15

      • Abstract

      No abstract available for this presentation

    • +

      IS10.03 - MODULE 3: Optimal Use of Recently Approved RET Inhibitors in the Care of Patients with RET-Positive NSCLC

      06:15 - 06:30

      • Abstract

      No abstract available for this presentation

    • +

      IS10.04 - MODULE 4: Rational Approaches to Targeting MET Abnormalities for Patients with NSCLC

      06:30 - 06:45

      • Abstract

      No abstract available for this presentation

  • +

    OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation

    • 18:45 - 19:45
    • 9/12/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      OA15.02 - Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations

      18:55 - 19:05  |  Presenter: Pasi A. Janne

      • Abstract

      Loading...

    • +

      OA15.04 - Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer

      19:15 - 19:25  |  Presenter: D. Ross Camidge

      • Abstract

      Loading...